Why the study?
Does verapamil plasma concentration correlate with P-R prolongation in patients with essential hypertension?
Does verapamil plasma concentration correlate with P-R prolongation in patients with essential hypertension?
Oral verapamil therapy in essential hypertension causes transient P-R prolongation that correlates with plasma concentration, but does not lead to high-grade AV block.
Answers are grounded in this paper and cite their sources.
May warrant PR monitoring with verapamil in hypertension; leaves open whether concentration-guided dosing improves safety.
Plasma verapamil concentration was correlated with serial electrocardiographic P-R intervals in patients with essential hypertension receiving immediate-release (80 to 120 mg three times a day) or sustained-release (240 mg daily) verapamil. The mean P-R interval in 22 patients taking placebo and immediate-release verapamil was 0.18 second. The borderline first-degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P-R interval longer than 0.20 second and of those with a P-R interval of 0.20 second or less were 169 +/- 73 ng/mL and 63 +/- 8 ng/mL, respectively. Six patients taking sustained-release verapamil had a maximal mean P-R interval of 0.19 +/- 0.01 second during 24-hour ambulatory electrocardiographic monitoring. P-R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P-R prolongation occurred with oral verapamil therapy, but no patient, regardless of baseline P-R interval, developed high-grade atrioventricular block.
No takes yet. Share an insight, caveat, or question.
Zachariah et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: